Cost Analysis: Is it still Cost Effective to Use Prasugrel or Ticagrelor vs. Generic Clopidogrel? - David J. Cohen, MD

↳ This is a section part of Moment: CRT 2015 Coronary - Antiplatelet Controversy For ACS: How will this iMPACT our Practice?

Add this Moment to your Passport

Learn from this moment and keep it forever.
Add To Passport
$19.99
This moment is included in Simple Premium - Get started for free.
FREE with Simple Premium
Start your 30-day free trial
Simple Premium offers unlimited access to all premium moments. $30.00 per month. Cancel anytime.

Preview

Summary

Cost Analysis: Is it still Cost Effective to Use Prasugrel or Ticagrelor vs. Generic Clopidogrel? presented by David J. Cohen, MD at CRT 2015

Add this Moment to your Passport

Learn from this moment and keep it forever.
Add To Passport
$19.99
This moment is included in Simple Premium - Get started for free.
FREE with Simple Premium
Start your 30-day free trial
Simple Premium offers unlimited access to all premium moments. $30.00 per month. Cancel anytime.

Target Audience

  • Interventional Cardiologists
  • Interventional Fellows

Session Name: Antiplatelet Controversy For ACS: How will this iMPACT our Practice?

Track: Coronary

Learning Objectives

  • Update in advances in ACS & AMI Management

Other Components in this Moment

Overview
Emerging Protocols for Antiplatelet Therapy in ACS and During PCI - Roxana Mehran, MD
Why I Prefer Ticagrelor - Gary L. Schaer, MD
Why I Prefer Prasugrel - D. Angiolillo, MD, PhD
What Should Be the Role of Cangrelor in PCI Post-FDA Advisory Panel? - Neal S. Kleiman, MD
Cost Analysis: Is it still Cost Effective to Use Prasugrel or Ticagrelor vs. Generic Clopidogrel? - David J. Cohen, MD
Switching Back to Clopidogrel: Whether and When? - Paul A. Gurbel, MD
Pharmacotherapy for Patients with Atrial Fibrillation Who Receive Stents: Mix and Match? - C. Michael Gibson, MD
High Dose Tirofiban: Should it be Our Preferred GPI? - George W. Vetrovec, MD
Will The Results Form the DAPT Study Will Impact on the Duration Of DAPT in ACS Patients? - Dean J. Kereiakes, MD
Is There a Role for Antiplatelet Therapy with Vorapaxar Following ACS? - Sunjay Kaul, MD
Loading Simple Education